Search Results

Natco Pharma Limited, a research and development -focused pharmaceutical company based in India, announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.

Fosun Pharma USA Inc. (“Fosun Pharma USA”) is pleased to announce that Chief Executive Officer, Rong Yang, and several Fosun Pharma USA executives, will be attending the 42nd Annual J.P. Morgan Healthcare Conference (JPM ’24), taking place in San Francisco, California, Jan. 8 - 11, 2024.

Poolbeg Pharma announces that, further to its announcement on20 March 2024,the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical stage assets, further solidifying the relationship between the two companies.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).